Nuvation Bio FY2025 EPS Forecast Lifted by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Equities research analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Nuvation Bio in a report issued on Thursday, December 11th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.63) per share for the year, up from their prior estimate of ($0.64). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.34) EPS.

Several other research firms have also issued reports on NUVB. JMP Securities set a $10.00 target price on shares of Nuvation Bio in a report on Thursday, November 20th. Truist Financial set a $11.00 price objective on shares of Nuvation Bio in a research report on Monday, November 24th. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a research note on Tuesday, November 4th. Royal Bank Of Canada upped their target price on Nuvation Bio from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. Finally, Citizens Jmp increased their price target on Nuvation Bio from $8.00 to $10.00 and gave the stock a “market outperform” rating in a report on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Nuvation Bio has an average rating of “Moderate Buy” and a consensus price target of $10.56.

Nuvation Bio Trading Up 2.2%

NUVB stock opened at $8.70 on Monday. Nuvation Bio has a twelve month low of $1.54 and a twelve month high of $8.95. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of -13.59 and a beta of 1.58. The company has a quick ratio of 8.39, a current ratio of 8.48 and a debt-to-equity ratio of 0.14. The firm’s fifty day simple moving average is $5.88 and its two-hundred day simple moving average is $3.77.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $13.12 million for the quarter, compared to analyst estimates of $7.48 million. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%.

Institutional Investors Weigh In On Nuvation Bio

Hedge funds have recently made changes to their positions in the company. Highline Wealth Partners LLC purchased a new position in shares of Nuvation Bio during the second quarter valued at $25,000. Rangeley Capital LLC purchased a new stake in Nuvation Bio in the second quarter worth about $25,000. Parallel Advisors LLC grew its holdings in Nuvation Bio by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after acquiring an additional 2,597 shares in the last quarter. Cetera Investment Advisers purchased a new position in Nuvation Bio during the 2nd quarter valued at about $29,000. Finally, Captrust Financial Advisors purchased a new position in Nuvation Bio during the 2nd quarter valued at about $32,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Nuvation Bio

In other news, insider Gary Hattersley sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $5.02, for a total transaction of $502,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Dongfang Liu sold 150,000 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.82, for a total value of $1,173,000.00. Following the completion of the sale, the insider owned 18,000 shares of the company’s stock, valued at $140,760. The trade was a 89.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,000 shares of company stock worth $2,050,800 over the last 90 days. Insiders own 29.93% of the company’s stock.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.